A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers

This study has been completed.

Study NCT00000871 Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

First Received: November 2, 1999 Last Updated: December 19, 2008 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Study Completion Date:	January 2000
Primary Completion Date:	January 2000 (Final data collection date for primary outcome measure)